Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRECORIDER		DATIFALT
PRESCRIBER		PATIENT:
Name:		Name:
Ward:		NHI:
Budesonide		
INITIATION – Crohn's disease Prerequisites (tick boxes where a	ppropriate)	
Mild to moderate ile	eal, ileocaecal or proximal Crohn's disease	
O Diabetes or O Cushingoid h or O Osteoporosis	nabitus s where there is significant risk of fracture	
or O History of set or O History of ma causing relap	following treatment with conventional cortico were psychiatric problems associated with co ajor mental illness (such as bipolar affective of ose is considered to be high ang pregnancy (where conventional corticoste	rticosteroid treatment lisorder) where the risk of conventional corticosteroid treatment
Prerequisites (tick box where app	rmphocytic colitis (microscopic colitis) ropriate) f microscopic colitis (collagenous or lymphoc	cytic colitis) by colonoscopy with biopsies
INITIATION – Gut Graft versus Herequisites (tick box where app		arrow transplantation

I confirm that the above details are correct:

C:	D-1	
Signed.	Date:	
Oigilica.	 Daic.	

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:			
Name:	Name:			
Ward:	NHI:			
Budesonide - continued				
INITIATION – non-cirrhotic autoimmune hepatitis Re-assessment required after 6 months Prerequisites (tick boxes where appropriate)				
O Patient has autoimmune hepatitis*				
and Patient does not have cirrhosis and				
O Diabetes				
Cushingoid habitus				
Osteoporosis where there is significant risk of fracture				
Or Severe acne following treatment with conventional corticosteroid therapy				
O History of severe psychiatric problems associated wi	ith corticosteroid treatment			
causing relapse is considered to be high	etive disorder) where the risk of conventional corticosteroid treatment			
O Relapse during pregnancy (where conventional corti	costeroids are considered to be contraindicated)			
O Adolescents with poor linear growth (where conventi	ional corticosteroid use may limit further growth)			
Note: Indications marked with * are unapproved indications.				
CONTINUATION – non-cirrhotic autoimmune hepatitis Re-assessment required after 6 months Prerequisites (tick box where appropriate)				
O Treatment remains appropriate and the patient is benefitting from the treatment				

I confirm that the above details are correct:

C:	D-1	
Signed.	Date:	
Oigilica.	 Daic.	